Drug Diaries

In this conversation, Chema and Kaushik explore the evolving landscape of the pharmaceutical industry, emphasizing the importance of patient-centric approaches and the integration of technology in enhancing patient experiences. They discuss the challenges faced by the industry, the need for empathy, and the significance of understanding patient behavior. Personal anecdotes highlight the impact of their work, showcasing the human side of healthcare and the potential of digital therapeutics to transform patient engagement.Takeaways - The pharmaceutical industry is undergoing significant changes, requiring a shift towards patient-centric approaches. Empathy is crucial in understanding and addressing patient needs in healthcare. Technology plays a vital role in enhancing patient experiences and engagement. Personal stories can illustrate the real impact of pharmaceutical work on patients' lives. Understanding patient behavior is essential for effective communication and engagement strategies. Digital therapeutics (DTx) have the potential to revolutionize patient care and information access. The industry must move beyond traditional metrics to measure success in patient engagement. Collaboration with health patients is necessary for meaningful change in the industry. There is a need to break down assumptions about patient behavior based on demographics. The future of healthcare lies in understanding and responding to individual patient needs. If you'd like to sponsor the show and elevate your brand with our audience, reach out to show host Kaushik Trivedi on LinkedIn and his team will reach out to fix up a chat to explore.Connect with José Ma. (Chema) Guido Avila:LinkedIn: https://www.linkedin.com/in/josemariaguido/Connect with Kaushik Trivedi:Instagram: https://www.instagram.com/drugdiaries_/Linkedin: https://www.linkedin.com/in/kaushiktrivedi/

The video explores how artificial intelligence is transforming healthcare, with AI handling routine tasks to let humans focus on more critical work. This shift highlights the powerful synergy between technology and human expertise, driving significant healthcare innovation. Over 65% of pharma leaders report AI influencing real-time decisions, showcasing its impact on patient outcomes. The future of AI in healthcare emphasizes coordinated teamwork for better patient care. Chapters 00:00 – The Future of AI + Human Healthcare 01:18 – What Will AI Really Change? Hype vs Reality 02:08 – Welcome to Drug Daddies 02:29 – A Heartfelt Message: 93% Haven’t Subscribed 03:15 – Healthcare’s Silent AI Revolution 04:18 – AI Has Already Changed Healthcare 04:52 – Guest Introduction: Mohammed Haq, Cognizant 05:39 – Mohammed’s Journey + 30 Years of Experience 06:32 – The Perception Gap: People Think AI Is Future, Not Present 07:04 – The Biggest Misunderstanding About AI 08:49 – Fear of AI Replacing Jobs vs Reality of Augmentation 09:36 – Why AI Doesn’t Replace Clinicians 10:03 – The Power of Human + AI Teamwork 10:32 – The Moment AI Proved Itself: AlphaFold Breakthrough 11:28 – What’s Actually Real Today vs Still Hype 12:48 – The 6-Step Framework to Separate Signal from Noise 13:36 – Outcomes Matter: How to Evaluate AI Claims 15:15 – Winners Ask: Does AI Make Us Faster, Smarter, More Human? 15:40 – Where AI Is Saving Time, Money, and Lives 16:09 – Cognizant’s 3-Vector AI Strategy Explained 17:51 – Where AI Delivers the Most Value Across Pharma 18:17 – Using All 3 Vectors: What Clients Are Doing Today 19:29 – Agentic AI: How Mature Are These Technologies? 20:24 – Partnerships with NVIDIA, Microsoft, Google 21:53 – Why Ecosystems Win: AI at Global Scale 22:20 – What Patients Really Think About AI 23:46 – From Output to Action: The Rise of AI Agents 24:17 – Next 24 Months: Where AI Will Reshape Pharma 25:56 – The Real Barriers: Not Technology, Mindset 26:43 – BlueBolt: 53,000 People Building 30,000 AI Prototypes 28:09 – Culture Shift: Curiosity, Safety, and Innovation 28:37 – Which AI Use Cases Are Boardroom-Ready 29:30 – Clients Now Want Outcomes, Not Pilots 31:18 – The Market Is Changing Faster Than Ever 31:40 – Culture Eats Tech for Breakfast 32:38 – Democratizing Innovation at Cognizant 33:02 – How Leaders Build Safe + Ambitious AI Teams 33:37 – Predicting the Biggest Breakthrough in 2 Years 34:54 – The Excitement and Risks of AI in Healthcare 36:09 – AI: The New Electricity of Business 37:02 – Final Reflections: AI Completes Human Empathy 37:27 – Inspiring Close: AI Will Amplify the Human Heartbeat

The discussion highlights how "most favored nation" policies have evolved from theoretical policy discussions into tangible business challenges. This shift significantly impacts the "pharmaceutical industry", particularly concerning global strategies and "regulatory compliance". The conversation also delves into the implications of these policies, including the introduction of "tariffs", on international business practices. Chapters 00:00 – The Moment MFN Became Real A senior pharma leader’s launch dilemma turns MFN from theory into a business-critical threat. 02:50 – What Is MFN, Really? (Explained Simply) Chris breaks down MFN in plain language—and why it is not global price harmonisation. 05:00 – Explaining MFN to a 12-Year-Old Simple analogies that cut through the policy complexity. 07:30 – What Problem Is MFN Trying to Solve? Is MFN about affordability, fairness, leverage—or something else entirely? 10:00 – Will MFN Actually Lower Patient Out-of-Pocket Costs? Separating political rhetoric from real patient impact. 12:15 – MFN vs Recent ‘MFN-Like’ Pharma Deals Why recent Pfizer, AstraZeneca, and EMD agreements are not true MFN—and why that matters. 15:15 – Does MFN Reduce Prices or Just Shift Who Pays? Who really benefits: patients, governments, or budgets? 18:15 – “Europe Becomes a Risk, Not a Launch Anchor” Why global launch sequencing is being fundamentally rethought. 20:30 – The Global Ripple Effect: Who Feels MFN First? Which countries are most exposed—and why affordability has limits. 23:45 – MFN and R&D: What Innovation Gets Funded Next? How MFN could quietly reshape drug development priorities. 27:00 – Launch Sequencing, Evidence Strategy & Uncertainty Why companies must plan multiple launch paths simultaneously. 29:30 – Will MFN Spill Into Commercial Pricing? How Medicare and Medicaid policies may reshape the entire US market. 32:00 – Value-Based Pricing in an MFN World Why MFN complicates outcomes-based and value-based contracts. 34:30 – Confidential Discounts Under Threat Could MFN break the global confidential contracting model? 37:15 – Why Value Means Different Things in Different Countries How HTA frameworks, PICO, and comparators collide under price referencing. 40:00 – Could the World Move Toward Standardised Drug Pricing? The iPhone analogy—and why drugs are different. 42:40 – Extreme but Plausible MFN Scenarios (US Perspective) What “MFN-light” vs “MFN-heavy” futures could look like. 45:00 – Extreme but Plausible MFN Scenarios (Global Perspective) Where affordability breaks—and access risks emerge. 47:30 – The One Thing CEOs Should Do Now Scenario planning, signposts, and future-proofing launch strategy. 50:30 – Final Takeaways: MFN Is Not a Policy to Watch—It’s a Shift to Prepare For Why waiting is the biggest risk of all.

In this conversation Marek Rombel explains the importance of translating complex strategies into actionable steps for execution, emphasizing the role of cross-functional teams in ensuring clarity and effectiveness in product launches. takeaways A third of products launched are unsuccessful. Translating data and strategy is crucial for execution. Complex strategies can confuse customers if not simplified. Cross-functional teams are essential for distilling strategy. Effective execution requires clarity and simplicity. Being a great strategist also means being a great executionalist. Execution involves taking complex ideas and making them accessible. Customer confusion can stem from overly complex strategies. Successful product launches depend on clear communication. Collaboration across teams enhances execution effectiveness. Chapters 00:00 The Hidden Side of Success in Life Sciences 06:27 Lessons from a Seasoned Strategist 13:00 The Importance of Cross-Functional Collaboration 18:54 Market Conditioning and Messaging Strategies 23:29 Navigating Challenges in a Complex Landscape 27:55 Advice for Biotech Founders on Commercialization 33:52 Navigating Launch Challenges 38:19 The Importance of Empathy in Strategy 45:45 Building Collaborative Partnerships

In this conversation, Jill Donahue discusses the importance of influence and engagement in everyday interactions, emphasizing that serving others is key to finding purpose and achieving effective communication.

In this enlightening conversation, Dr. Ivan Diaz-Padilla shares his journey from clinician to global oncology leader, discussing the unpredictable nature of cancer research, the emotional resilience required in oncology, and the complexities of drug discovery. He emphasizes the importance of biomarkers, the challenges of immuno-oncology, and the need for patient-centric clinical trials. The discussion also touches on the global disparities in cancer treatment access and the hopeful advancements in cancer care that may redefine the future of oncology. Chapters 00:00 The Unexpected Truths of Cancer Research 02:11 The Journey from Bedside to Boardroom 03:45 Inflection Points in a Medical Career 05:39 The Transition from Clinician to Industry 08:08 Emotional Resilience in Oncology 09:50 Understanding the Drug Development Process 12:59 The Evolution of Immuno-Oncology 17:46 The Complexity of Combination Therapies 22:24 The Role of Biomarkers in Personalized Medicine 26:10 Balancing Ethics and Rigor in Clinical Trials 30:37 Patient-Centric Approaches in Clinical Trials 35:25 Learning from Clinical Trial Failures 38:23 Transformational Insights from Setbacks 41:58 The Role of AI in Oncology 46:29 Closing the Global Gap in Cancer Access 48:54 Optimism for the Future of Cancer Care 53:02 Legacy and Contributions to Oncology

In this conversation, Ewelina Kurtys discusses her journey into biocomputing, a field that merges neuroscience and artificial intelligence. She explains the concept of biocomputing, the role of living neurons in computation, and the philosophical implications of AI and consciousness. The discussion also covers the challenges of programming neurons, safety concerns, and the future potential of biocomputing in various applications. Ewelina emphasizes the importance of ethical considerations and the collective responsibility of scientists to ensure that their work benefits society. Chapters 00:00 The Emergence of Biological Intelligence 02:32 Evelina Kotes: A Journey into Biocomputing 06:02 Philosophy of Intelligence and Consciousness 10:04 Understanding Biocomputing 15:39 Neurons: The Building Blocks of Intelligence 18:09 The Butterfly Experiment: A Living Demo 20:34 Misconceptions About AI and Biocomputing 23:18 Safety and Reproducibility in Biocomputing 25:22 Challenges of Neuron Longevity and Maintenance 26:46 The Human Side of Frontier Science 28:41 Energy Efficiency and Cost of Biocomputing 30:55 Emerging Use Cases for Biocomputing 32:04 Programming Neurons for Advanced Algorithms 35:39 The Future of Biocomputing and Its Impact 37:48 Quality of Neurons: Lab vs. Natural 39:31 Moments of Pride in Scientific Discovery 43:38 The Deeper Meaning of Biocomputing

In this conversation, Kaushik Trivedi interviews Dr. Aubrey de Grey, a prominent figure in longevity science, who challenges the conventional view of aging as an inevitable process. Dr. de Grey presents aging as an engineering problem that can be solved through advancements in technology, particularly in AI and nanotechnology. He discusses the concept of longevity escape velocity, where life expectancy could increase faster than aging, and emphasizes the interconnectedness of aging and diseases. The conversation also explores societal attitudes towards aging, the role of the pharmaceutical industry, and the moral obligation to address the suffering caused by aging. Dr. de Grey's vision for the future includes a shift in public perception and the potential for significant advancements in longevity research. 00:00 Challenging the Inevitability of Aging 02:28 Aubrey de Grey: A Visionary in Longevity Science 05:02 The Turning Point in Aging Research 06:17 Understanding Aging as Repairable Damage 08:00 Longevity Escape Velocity: A Mathematical Perspective 12:40 The Role of Nanotechnology and AI in Aging 15:48 Misunderstandings About Aging 17:12 The First Person to Live to a Thousand 19:11 The Seven Types of Aging Damage 24:06 Exciting Experiments in Aging Research 24:55 Integrating Components for Longevity Research 28:16 The Science of Caloric Restriction and Aging 29:56 The Psychological Barriers to Curing Aging 33:40 Navigating Skepticism in Aging Research 36:39 The Future of Longevity and Societal Change 39:32 Pharma's Role in Longevity Therapies 42:22 Reimagining Life with Extended Longevity 44:26 Aubrey De Grey's Vision for the Future 46:00 Key Messages on Aging and Suffering

Every 1.8 seconds, someone dies from heart disease, many of them never saw it coming.They were healthy, active, doing everything “right”… yet still at risk from the silent killer inside their arteries. In this powerful episode of Drug Diaries, host Kaushik Trivedi sits down with world-renowned cardiology expert Professor Maciej Banach to uncover the truth about cholesterol, heart disease, and prevention. Together, they explore: Why cholesterol isn’t the villain we think it is and what really makes it dangerous The crucial role of LDL cholesterol in atherosclerosis and heart attacks Why early detection and awareness can save millions of lives How innovations like gene editing and new cholesterol treatments are changing the future of heart health The lifestyle changes and small daily actions that can dramatically reduce your risk This conversation breaks down complex science into simple truths — helping you understand your body, your risks, and the steps you can take to protect your heart. 💡 Key Takeaways: Heart disease often strikes silently, without symptoms. Cholesterol is essential, but balance is everything. Awareness is prevention. Lifestyle and early testing save lives. Science is evolving fast but understanding remains our greatest tool. 🎙️ Chapters: 00:00 – The Silent Killer: Understanding Heart Disease 10:28 – Cholesterol: The Essential Molecule Misunderstood 21:08 – Early Detection: The Key to Prevention 25:39 – Innovations in Cholesterol Treatment 30:27 – Understanding LDL Cholesterol and Atherosclerosis 41:50 – The Multifaceted Nature of Cardiovascular Risk 48:56 – Bridging the Gap: From Knowledge to Action 55:48 – Personal Reflections and Motivations in Cardiology

Summary In this enlightening conversation, Carlos Eid shares his journey into medical affairs, emphasizing the importance of redefining impact beyond mere activity metrics. He discusses the evolving role of Medical Science Liaisons (MSLs), the integration of AI in medical affairs, and the significance of cultural sensitivity in leadership. Carlos also highlights the value of mentorship and personal growth, urging the next generation to find their purpose and remain resilient in their careers. His insights reflect a deep commitment to patient-centricity and the transformative potential of medical affairs in healthcare. Chapters 00:00 The Evolving Role of Medical Affairs 02:14 Personal Journeys in Medical Affairs 06:34 Rethinking Impact in Medical Affairs 15:39 Defining Exceptional MSLs 25:58 The Balance of Human Insight and AI 28:06 AI as an Enabler in Medical Writing 30:26 Leadership Across Cultures 34:21 The Importance of Mentorship 37:38 Evolution of Leadership Style 40:06 Addressing Non-Performance 42:43 Core Values and Personal Identity 47:27 Advice for the Next Generation in Medical Affairs

summary In this conversation, Kaushik Trivedi and Rohit Alimchandani discuss the transformative impact of technology on healthcare, emphasizing the importance of leadership, team dynamics, and the role of AI in enhancing patient experiences. Rohit shares insights from his career journey, leadership philosophy, and the future of healthcare innovation, highlighting the need for a connected ecosystem to drive efficiency and improve patient outcomes. Chapters 00:00 Transforming Healthcare: The Role of Technology 02:55 Rohit Alimchandani's Career Journey 05:48 Leadership Philosophy and Influences 09:34 Building High-Performing Teams in Healthcare Tech 12:13 AI and Patient Empowerment 17:29 The Future of Drug Development and AI 22:21 Creating a Pharma Operating System 25:40 The Five Pillars of Pharmaceutical Innovation 31:15 Building a Connected Ecosystem in Pharma 35:45 Overcoming Silos in Pharmaceutical Technology 40:17 Engineering Impact in Healthcare 44:52 Metaphors for Digital Transformation 46:57 Future Trends in Healthcare Innovation Explore how **ai in healthcare** is impacting **medical innovation** and the future of **health technology**. **Automation** is reshaping processes, while **digital health** solutions drive **healthcare innovation** forward. Join the discussion on the latest **technology** reshaping medicine.

The AI revolution is no longer a future headline, it’s unfolding right now in every lab, every clinical trial, and every boardroom across the life sciences industry. In this short, powerful episode, Kaushik Trivedi explores: 💡 How AI is already transforming drug discovery, clinical development, and regulatory operations ⚡ The roles most at risk, and those that will thrive 🧭 The 3 new rules to future-proof your career in pharma and biotech 🗓️ A 12-month tactical roadmap to build AI fluency and become indispensable If you work in pharma, biotech, or healthcare, this episode could redefine how you think about your career, your value, and your future. 🎧 Watch till the end for a surprise call-to-action: a free 12-month roadmap + details on an upcoming AI Academy for Life Sciences Professionals. 👉 Comment “ROADMAP” below to get your copy and start your transformation today. #AI #Pharma #Biotech #FutureOfWork #LifeSciences #DigitalTransformation #DrugDiaries

Many wonder, what is cancer? This video explores the complexities of cancer research and the challenges in finding effective cancer treatment. It highlights the importance of early diagnosis of cancer and understanding various cancer symptoms. The video also touches on the impact on the cancer patient and the role of clinical trials. In this conversation, Dr. Sav Solanki shares his extensive journey in oncology, discussing the evolution of cancer treatment, the importance of mentorship, and the cultural breakthroughs that have shaped the field. He emphasizes the significance of patient-centric approaches and the role of collaboration in advancing oncology. The discussion also touches on the challenges of drug development, the impact of immunotherapy, and the future of cancer treatment, highlighting the need for innovation and understanding the human element in healthcare. takeaways Oncology is not just about science; it's about people. Mentorship plays a crucial role in career development. The evolution of cancer treatment has been significant over the years. Cultural breakthroughs in oncology are as important as scientific ones. Immunotherapy is changing the landscape of cancer treatment. Patient-centric approaches are essential for effective care. Collaboration across sectors is vital for progress in oncology. AI and data are transforming drug discovery and patient outcomes. Safety must always be prioritized in treatment development. Networking and continuous learning are key to career success. Chapters 00:00 The Human Element in Oncology 01:26 Sav Solanki's Journey in Oncology 03:42 Choosing the Path of Oncology 06:36 Mentorship and Learning in Oncology 09:00 Evolution of Cancer Treatment 12:30 Cultural Breakthroughs in Oncology 13:24 Collaboration in Cancer Research 15:35 The Power of Immunotherapy 17:58 Simplifying Complex Concepts 21:15 Holistic Approaches to Cancer Management 23:19 Patient-Centric Focus in Oncology 26:33 The Future of Data and AI in Cancer Treatment 27:44 Patient-Centric Approaches in Oncology 29:55 Barriers in Oncology Drug Development 32:56 Navigating the Drug Development Pipeline 34:34 Trade-offs in Treatment Development 36:10 Equity and Access in Oncology 39:53 The Future of Cancer Treatment 45:17 Collaboration in Oncology 46:19 Career Advice in Oncology 49:05 Guiding Principles in a Career

In this episode of Drug Diaries, Geert Kersten, CEO of Cel-Sci, discusses the innovative approach of using immunotherapy, specifically Multikine, in cancer treatment. He emphasizes the importance of the immune system in fighting cancer and the need for a paradigm shift in how cancer therapies are developed and administered. The conversation covers the challenges faced in drug development, regulatory hurdles, and the potential impact of Multikine on head and neck cancer treatment. Geert also shares insights on the evolving healthcare landscape in Saudi Arabia and the future aspirations for Multikine and Cel-Sci. Chapters 00:00 The Journey of Immunotherapy in Cancer Treatment 09:24 Understanding Multikine and Its Impact on Head and Neck Cancer 18:56 The Science Behind Multikine: Mechanism and Administration 23:27 Navigating Challenges: Regulatory Hurdles and Market Dynamics 26:21 FDA Feedback and Study Design 29:21 Commercial Aspirations and Future Vision 31:36 Saudi Arabia's Healthcare Vision 2030 35:04 Breakthrough Designation Explained 37:40 Multikine's Role in Cancer Treatment 41:03 Dealing with Doubt and Investor Skepticism 44:53 The Future of Leap Platforms 46:48 Long-term Impact of Multikine

In this conversation, the speakers discuss the importance of balancing structure and freedom in customer interactions, particularly in sales roles. They emphasize the need for preparation and context to build meaningful relationships with customers, moving beyond transactional interactions. The discussion also touches on the challenges faced during customer appointments, the significance of understanding customer concerns, and the role of gender equality in leadership. The speakers advocate for creating a supportive environment for women in the workplace and highlight the impact of leadership on diversity and inclusion. They conclude with reflections on authenticity, listening, and resilience as key leadership philosophies. takeaways Make every interaction count to build strong relationships. Preparation and context are crucial for effective sales meetings. Focus on the customer's needs rather than just ticking boxes. Building relationships requires a holistic approach to customer interactions. Understanding customer concerns fosters trust and engagement. Gender equality in leadership is essential for progress. Supportive environments empower women in the workplace. Leaders should be held accountable for diversity and inclusion targets. Authenticity and listening are vital for effective leadership. Resilience is key; don't compromise on your beliefs. Chapters 00:00 Balancing Structure and Freedom in Customer Interactions 02:20 The Importance of Preparation and Context in Sales Meetings 05:14 Building Relationships Beyond Transactions 08:05 Navigating Customer Appointments and Expectations 10:36 Understanding Customer Concerns and Community Engagement 13:38 Gender Equality and Leadership Challenges 16:04 Creating a Supportive Environment for Women in the Workplace 19:02 The Role of Authenticity in Leadership 21:46 Driving Change Through Accountability in Diversity Initiatives 25:13 Philosophy of Leadership and Resilience

In this conversation, Uday discusses the evolving landscape of leadership in the life sciences sector, emphasizing the importance of cultural collaboration, shared leadership, and the need for empathy and vulnerability in leadership roles. He highlights the challenges posed by hierarchical structures and the critical role of customer experience in healthcare. Uday also addresses the significant gap in diversity and inclusion within pharma leadership and advocates for a more authentic and inclusive approach to leadership. The discussion culminates in reflections on personal philosophies and actionable insights for fostering a more equitable future in the industry.

In this video, Dr. Arup Pramanik explains the crucial need to improve the **patient experience** so that new **drug development** efforts can have the greatest impact on the **patient journey**. They also emphasize the importance of using **artificial intelligence** and **ai** in **drug discovery** and **analytics** to speed access to vital medicines. takeaways Behind every life-saving medicine, there's a question of access. Market access is a complex mix of various expertise. Leadership requires honesty, empathy, and the ability to challenge. Innovation in healthcare must involve multiple stakeholders. AI can enhance patient care and improve healthcare outcomes. Health equity is crucial for inclusive healthcare access. Understanding the science and economics is key to market access. Building trust and relationships is essential for success. Success is measured by the growth of the teams you lead. Asking questions is vital for learning and growth. Chapters 00:00 The Battle for Market Access 02:44 Leadership Lessons from a Market Access Expert 05:34 Demystifying Market Access 08:10 Innovation in Pricing and Access Models 10:41 The Future of Healthcare: AI and Digital Transformation 13:56 Health Equity and Access in Low-Income Countries 16:39 Redesigning Market Access 19:07 Personal Growth and Leadership Philosophy 21:52 Measuring Success and Legacy 24:16 Advice for Future Leaders

Theory of Constraints, systems thinking, drug discovery, clinical trials, AI in pharma, organizational improvement, leadership, human potential, bottlenecks, healthcare innovation In this episode of Drug Diaries, Dr. Alan Barnard discusses the Theory of Constraints (TOC) and its application in high-stakes industries like pharmaceuticals. He emphasizes the importance of identifying and addressing the weakest link in a system to unlock human potential and improve overall performance. The conversation explores the challenges organizations face in recognizing constraints, the role of AI and robotics in overcoming bottlenecks, and the need for a shift in mindset to embrace new technologies and methodologies for continuous improvement. Chapters 00:00 The Reality of Life Science Challenges 02:07 Understanding the Theory of Constraints 05:54 Identifying and Managing Constraints 11:09 The Importance of Attention as a Resource 17:23 The Challenge of Improving Systems 21:01 Recognizing and Resolving Constraints 24:21 Applying TOC to Clinical Trials 28:24 TOC for Continuous Improvement in Successful Companies 30:29 Understanding Inventory Management and Flow 33:20 The Theory of Constraints: Mindset and Application 35:14 AI and Robotics: Transforming Capacity Constraints 36:53 Digital Twins: The Future of Drug Testing 39:05 Overcoming Limitations with Technology 42:15 Courage to Focus on What Matters 44:26 Redefining Success: Personal and Professional Goals I look forward to receiving your feedback! Many thanks Kaushik

In this conversation, Florian Schnappauf discusses the evolving landscape of the pharmaceutical industry, emphasizing the need for a shift in mindset and strategy as companies prepare for an influx of product launches by 2030. He highlights the importance of connected functions, the role of AI in enhancing customer engagement, and Veeva's strategic move to its own Vault platform for CRM. The discussion also covers the challenges posed by specialty medicines, the necessity of effective content management, and the importance of a unified view of healthcare professionals to improve interactions. Schnappauf concludes with insights on the future of pharma operations and the mindset shifts required for success. Chapters 00:00 The Future of Pharma: A Crossroad 02:36 Transforming Mindsets in Life Sciences 04:57 The 2030 Launch Challenge 08:07 Specialty Medicines: A Dual Challenge 10:41 Risks of Traditional Launch Playbooks 13:19 Connecting Functions for Smarter Launches 16:04 Creating a Unified View of HCPs 18:36 Enhancing HCP Experience Through Technology 21:22 The Role of Content in Pharma Engagement 23:50 The Impact of AI on Pharma Interactions 26:31 Viva's Strategic Move to Vault Platform 30:32 Innovating for the Life Sciences Industry 34:22 Milestones in Vault CRM Adoption 36:07 Customer Feedback and Migration Challenges 38:29 The Role of AI in CRM 41:30 Practical AI Applications in CRM 45:56 Voice Control and Compliance Innovations 49:54 Campaign Manager and Service Center Innovations 55:06 Mindset Shifts for Pharma Leaders by 2030 56:50 Redesigning Pharma Launch Strategies

In this conversation, Thane Wetting, CEO of Fibrogen, shares his journey from academia to leading a biotech company focused on innovative treatments for oncology and anemia. He discusses the challenges and opportunities in transitioning from big pharma to a nimble biotech environment, emphasizing the importance of patient-centricity, leadership, and resilience. Thane reflects on the current biotech landscape, the role of the FDA, and the significance of maintaining a clear mission amidst market volatility. He also offers insights into investor relations and the importance of having the right people in the right roles to drive success. Chapters 00:00 The Mission Behind Fibrogen 02:18 Thane Wetting's Career Journey 16:58 Transitioning from Big Pharma to Biotech 21:02 Leadership Transition at Fibrogen 30:22 Understanding Prostate Cancer 33:05 Sustaining Core Values During Change 36:09 Navigating Organizational Change and Virtual Transition 38:33 Innovations in Oncology: ADC and Imaging Agents 42:07 Global Expansion and Commercialization Strategies 45:30 Balancing Scientific Ambition with Commercial Realism 49:21 Navigating a Cautious Capital Environment 51:40 FDA Interactions and Regulatory Responsiveness 53:42 Investor Behavior and Risk Management 56:02 Reflections on Career Lessons and Personal Growth 59:25 Advice for Emerging Leaders in Biotech 01:03:29 Staying True to Purpose in Biotech